Announced
Financials
Tags
Biotechnology
Private Equity
immunotherapy
United States
biotechnology
Single Bidder
Pending
Friendly
Autologous Cell Therapy
Acquisition
Domestic
Majority
De-SPAC
Private
Merger
Reverse Takeover
Synopsis
NKMax-backed NKGen Biotech, a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK Natural Killer cell therapeutics, agreed to go public via a merger with Graf Acquisition, a blank-check company incorporated as a Delaware corporation and formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, in a $160m deal. “We are excited to partner with Sangwoo, Paul and the whole NKGen team to help realize their long-term potential. Graf has looked at numerous potential biotech companies and after reviewing NKGen’s science, differentiated manufacturing and cryopreservation technology, NKGen really stood out to our team. But what really resonated for us is NKGen’s commitment to developing treatments addressing unmet areas of neurodegenerative diseases,” James Graf, Graf CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.